Clinical trials: Niraparib
Ovarian Cancer
Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer
This is a single-center, prospective, single-arm clinical trial to evaluate the efficacy and safety of Huaier granules in combination with immunotargeted agents in postoperative patients with ovarian cancer.
- Trial name
- NCT05749211
- Testing
- Huaier granule
- Volunteers
- 59 people
- Sponsor
- Ruijin Hospital
Cancer Metastatic
Improving Public Cancer Care by Implementing Precision Medicine in Norway
IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as…
- Trial name
- IMPRESS-N (NCT04817956)
- Testing
- Atezolizumab
- Where
- 17 sites in Norway
- Volunteers
- 3,000 people
- Sponsor
- Oslo University Hospital
Ovarian Cancer
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
The main aim of this study is to check for side effects from treatment with niraparib. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what…
- Trial name
- NCT05021562
- Testing
- Niraparib
- Where
- Japan
- Volunteers
- 354 people
- Sponsor
- Takeda
Breast Cancer
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is…
- Trial name
- NCT05601440
- Testing
- RP-6306, Gemcitabine, Observation
- Where
- 10 sites in Canada
- Volunteers
- 484 people
- Sponsor
- Canadian Cancer Trials Group
Cancer
Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but life-threatening adverse events such as myelodysplastic syndrome (MDS) and/or acute myeloid…
- Trial name
- NCT04326023
- Testing
- PARP Inhibitors
- Where
- France
- Volunteers
- 178 people
- Sponsor
- University Hospital, Caen
Cancer
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce.
- Trial name
- NCT04774406
- Testing
- olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
- Where
- France
- Volunteers
- 2,336 people
- Sponsor
- University Hospital, Caen
Ovarian Cancer, Peritoneal Cancer
Real-life Use of Niraparib in a Patient Access Program in Norway
Retrospective observational study of patients treated with niraparib in an individual patient access program in Norway.
- Trial name
- NCT04785716
- Testing
- Niraparib
- Where
- Norway
- Volunteers
- 106 people
- Sponsor
- Kristina Lindemann
Neoplasms
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor, dostarlimab in the paediatric population.
- Trial name
- NCT04544995
- Testing
- Niraparib (Tablet for oral suspension), Dostarlimab, Niraparib (Tablet)
- Where
- 2 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Homologous Recombination Deficient Solid Tumors
Niraparib and Dostarlimab in HRD Solid Tumors
This is an open-label, single-arm, Phase 2 study which will evaluate the efficacy and safety of niraparib and dostarlimab (TSR-042) combination in patients with metastatic, recurrent, or unresectable solid tumor with a…
- Trial name
- DIDO (NCT04983745)
- Testing
- Combination drug
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- West Cancer Center
Ewing Sarcoma
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with…
- Trial name
- NCT02044120
- Testing
- niraparib, Temozolomide, Irinotecan
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Cancer
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious adverse events such as pancytopenia. Today, data about pancytopenia are scarce.
- Trial name
- NCT04774627
- Testing
- PARP inhibitor
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Caen
Epithelial Ovarian Cancer
The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer
1. To evaluate the efficacy and safety of niraparib in Korean women with primary and recurrent epithelial ovarian cancer who underwent niraparib maintenance therapy 2.
- Trial name
- REFIRM (NCT06086665)
- Testing
- Niraparib
- Where
- South Korea
- Volunteers
- 850 people
- Sponsor
- Asan Medical Center